Momenta Pharmaceuticals, Inc. (MNTA) Director Sells $154,280.00 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Elizabeth Stoner sold 7,714 shares of the business’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $20.00, for a total value of $154,280.00. Following the sale, the director now owns 29,378 shares of the company’s stock, valued at approximately $587,560. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Elizabeth Stoner also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Wednesday, March 21st, Elizabeth Stoner sold 3,399 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $19.00, for a total value of $64,581.00.
  • On Tuesday, April 10th, Elizabeth Stoner sold 3,399 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $19.00, for a total value of $64,581.00.
  • On Tuesday, January 30th, Elizabeth Stoner sold 16,264 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total value of $292,752.00.

Shares of MNTA opened at $19.45 on Monday. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $20.25. The company has a market capitalization of $1,514.11, a price-to-earnings ratio of -16.21 and a beta of 1.64.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The company had revenue of $64.60 million for the quarter, compared to analyst estimates of $66.59 million. During the same period in the prior year, the company posted $0.60 EPS. Momenta Pharmaceuticals’s quarterly revenue was up 88.9% on a year-over-year basis. equities research analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.27 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of Momenta Pharmaceuticals by 0.8% in the 4th quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock valued at $146,105,000 after purchasing an additional 82,691 shares in the last quarter. Palo Alto Investors LLC raised its position in shares of Momenta Pharmaceuticals by 1.5% in the 4th quarter. Palo Alto Investors LLC now owns 1,821,576 shares of the biotechnology company’s stock valued at $25,411,000 after purchasing an additional 26,578 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Momenta Pharmaceuticals by 9.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock valued at $22,083,000 after purchasing an additional 134,500 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in shares of Momenta Pharmaceuticals by 243.6% in the 4th quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock valued at $13,445,000 after purchasing an additional 683,296 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Momenta Pharmaceuticals by 6.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 897,784 shares of the biotechnology company’s stock valued at $16,609,000 after purchasing an additional 56,748 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

A number of research firms have weighed in on MNTA. Stifel Nicolaus upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $18.00 to $21.00 in a report on Thursday, February 22nd. BidaskClub upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, April 4th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, April 3rd. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $15.33.

COPYRIGHT VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Director Sells $154,280.00 in Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/16/momenta-pharmaceuticals-inc-mnta-director-sells-154280-00-in-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply